Syros Pharmaceuticals (SYRS) Misses Q2 EPS by 13c

Syros Pharmaceuticals (NASDAQ: SYRS) reported Q2 EPS of ($0.54), $0.13 worse than the analyst estimate of ($0.41). Revenue for the quarter came in at $6.28 million versus the consensus estimate of $4.74 million.

For earnings history and earnings-related data on Syros Pharmaceuticals (SYRS) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
• BMO starts chip stocks coverage: Here are its preferred picks